Medication info
Rosuvastatin Calcium 20 mg

Rosuvastatin Calcium 20 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201405052 · Approved 2014.10.30 · Insurance code 657805480

Summary

Main use
Treatment of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response; the dose may be increased to a maximum of 20 milligrams per day. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct when diet and exercise alone are insufficiently effective in patients with primary hypercholesterolemia and mixed dyslipidemia. It is also used as an adjunctive therapy along with diet or other lipid-modifying therapies in patients with homozygous familial hypercholesterolemia. Additionally, it helps to lower the total cholesterol and LDL cholesterol levels in hypercholesterolemic patients to target levels, thereby delaying the progression of atherosclerosis. It can be used in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia along with dietary management, as well as being beneficial for patients with primary dysbetalipoproteinemia. Furthermore, in males aged 50 years and older and females aged 60 years and older with cardiovascular risk factors, it aids in reducing the risk of stroke, myocardial infarction, and arterial revascularization. Thus, it is effectively used for various hyperlipidemia and cardiovascular risk conditions.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response; the dose may be increased to a maximum of 20 milligrams per day. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For example, patients who are allergic to this medication, patients with severely impaired liver function, patients with muscle disorders, patients taking certain immunosuppressants, patients with severe kidney dysfunction, women who are pregnant or breastfeeding, and patients with genetic issues such as lactose intolerance should not take this medication. Moreover, liver function tests and muscle-related tests should be regularly performed before and during treatment with this medication, and if there are any liver diseases or hypothyroidism, those conditions should be treated first. If symptoms of muscle pain or weakness occur, patients should immediately inform their doctor and undergo necessary tests. This medication should be used cautiously in individuals who consume excessive alcohol or have a history of liver disease, as well as in the elderly or patients with reduced kidney function. In addition, the risk of muscle injury may increase when taken with certain medications, so patients should consult with their doctor or pharmacist regarding concomitant medications. During treatment, abnormal symptoms such as liver dysfunction, muscle pain, skin rashes, or allergic reactions may occur, so patients should immediately consult with medical professionals if these symptoms arise. Specifically, although rare, severe skin reactions or liver damage may occur, requiring caution. Women who are pregnant or planning to become pregnant should not take this medication, and if pregnancy is confirmed during treatment, it should be discontinued immediately. It is also safer for breastfeeding women not to take this medication. In the case of overdose, there is no specific antidote, so treatment should be symptomatic and liver function and muscle enzyme tests should be conducted to manage the condition. Lastly, this medication may cause dizziness, so caution is required when driving or operating machinery. It is important to promptly consult with medical professionals regarding any changes in health status or abnormal symptoms during treatment.

Side effects

Hypersensitivity reaction, angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, drug eruption resembling lichen planus, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, ALT elevation, chest pain, muscle cramps, gout, erectile dysfunction, AST elevation, fatigue, numbness, dysesthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is important to store it at room temperature between 1°C and 30°C to maintain its efficacy.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.